ロード中...

Development of luspatercept to treat ineffective erythropoiesis

Luspatercept (Reblozyl) was recently approved for treating patients with transfusion-dependent lower-risk myelodysplastic syndrome (MDS) with ring sideroblasts (RS) and/or SF3B1 mutation who were not eligible for erythropoiesis-stimulating agents (ESAs) or patients for whom those agents failed. Lusp...

詳細記述

保存先:
書誌詳細
出版年:Blood Adv
主要な著者: Kubasch, Anne Sophie, Fenaux, Pierre, Platzbecker, Uwe
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2021
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948289/
https://ncbi.nlm.nih.gov/pubmed/33687432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002177
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!